Robbie Marcus
Stock Analyst at JP Morgan
(2.83)
# 423
Out of 4,829 analysts
159
Total ratings
100%
Success rate
14.99%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $4.75 | +47.37% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $98.22 | +6.90% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $13.67 | -12.22% | 6 | May 6, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $235 → $195 | $156.44 | +24.65% | 5 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $60.73 | -4.50% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $13.75 | +23.64% | 5 | Apr 4, 2025 | |
| MMSI Merit Medical Systems | Initiates: Overweight | $120 | $98.73 | +21.54% | 1 | Mar 28, 2025 | |
| COO The Cooper Companies | Maintains: Overweight | $120 → $110 | $84.45 | +30.26% | 4 | Mar 7, 2025 | |
| BAX Baxter International | Maintains: Neutral | $38 → $36 | $31.88 | +12.92% | 17 | Feb 21, 2025 | |
| SYK Stryker | Maintains: Overweight | $420 → $445 | $388.08 | +14.67% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $561.43 | +20.23% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $14 | $13.37 | +4.71% | 4 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $6.74 | +92.88% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $102.87 | +6.93% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $316.67 | +4.21% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $17.16 | +86.48% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $31.81 | +25.75% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $78 | $74.80 | +4.28% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $85.05 | -0.06% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $74.11 | +21.44% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $36.57 | +36.72% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $7.19 | +11.27% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $297.55 | -15.98% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $8.91 | +79.57% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.30 | +11.11% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $11.89 | +42.98% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $131.99 | -10.60% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $137.80 | +13.21% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $85.81 | +22.36% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $94.64 | -57.73% | 2 | May 5, 2020 |
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $4.75
Upside: +47.37%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $98.22
Upside: +6.90%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $13.67
Upside: -12.22%
Inspire Medical Systems
May 6, 2025
Maintains: Overweight
Price Target: $235 → $195
Current: $156.44
Upside: +24.65%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $60.73
Upside: -4.50%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $13.75
Upside: +23.64%
Merit Medical Systems
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $98.73
Upside: +21.54%
The Cooper Companies
Mar 7, 2025
Maintains: Overweight
Price Target: $120 → $110
Current: $84.45
Upside: +30.26%
Baxter International
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $31.88
Upside: +12.92%
Stryker
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $388.08
Upside: +14.67%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $561.43
Upside: +20.23%
Dec 17, 2024
Maintains: Overweight
Price Target: $9 → $14
Current: $13.37
Upside: +4.71%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $6.74
Upside: +92.88%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $102.87
Upside: +6.93%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $316.67
Upside: +4.21%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $17.16
Upside: +86.48%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $31.81
Upside: +25.75%
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $74.80
Upside: +4.28%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $85.05
Upside: -0.06%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $74.11
Upside: +21.44%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $36.57
Upside: +36.72%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $7.19
Upside: +11.27%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $297.55
Upside: -15.98%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $8.91
Upside: +79.57%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.30
Upside: +11.11%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $11.89
Upside: +42.98%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $131.99
Upside: -10.60%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $137.80
Upside: +13.21%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $85.81
Upside: +22.36%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $94.64
Upside: -57.73%